spacer
home > pmps > winter 2018 > the valley of death
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Valley of Death

The “Valley of Death” is a term I learned early on in the pharmaceutical industry as a developer of new therapeutic compounds. It refers to that period when moving from compound discovery to early-stage development, including pre-clinical toxicology and safety pharmacology studies, and few sources of money are available to keep programmes alive and people paid. At any point, a project can fall apart due to toxicity, costs, inactivity against targets, or several other unforeseen events. You may save a lot of mice in your preclinical efficacy animal models, but will you save humans with a safe drug? That is the key question.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

spacer
Randice Altschul
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Prometic Bioseparations are very pleased to introduce their new purpose built ecommerce platform (Webshop)!

Their goal was to build a platform that is easy to navigate, informative and one that makes their products and services easily accessible to researchers and laboratories worldwide. They also wanted to make ordering as quick and easy as possible to meet the needs of the rapidly progressive industry. They have reflected these requirements with an ecommerce store in order to supply high quality products to customers from academia to big pharma.
More info >>

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

 
Industry Events

RDD Asia 2018

14-15 November 2018, Grand Hyatt Kochi, Kerala, India

A must-attend meeting for pulmonary and nasal researchers, inhaled product developers and vendors active in this important pharmaceutical niche.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement